Insilico Medicine, an end-to-end AI-powered drug discovery company, has announced the appointment of Dr. Michelle Chen to the company’s position of Chief Business Officer. In this role, Dr. Chen will oversee the company’s corporate strategies and business development activities. Dr. Chen brings more than 20 years of extensive experience in both biopharma and technology industries.…
Insilico Medicine, an end-to-end artificial intelligence (AI)-powered drug discovery company, announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO) to oversee capital markets, investor relations, financial operations, and corporate development. “It is an honor to join a pioneering company at the forefront of innovation in drug discovery. Insilico is leveraging its AI platform to accelerate…
Insilico Medicine, an end-to-end AI-powered drug discovery company, has announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical pipeline assets. Dr. Spiegel brings over 35 years of extensive R&D executive and operational experience in biopharmaceuticals and as an advisor to venture capital and private equity firms. “It…
Insilico Medicine, an end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development company, has announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing was also participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD…